SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
As per attached letter.02-01-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
As per attached letter.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issuance of duplicate share certificateSUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
Intimation for closure of Trading WindowSUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issuance of duplicate share certificate, as per letter attached.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per attached letter.Sun Pharma extends gains on $30-mn deal to buy Lyndra Therapeutics stake
The acquisition is expected to be completed by the end of December 2023, subject to certain conditions.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation of agreement to acquire stake in Lyndra Therapeutics, Inc.Sun Pharma, Lupin recall drugs in US over manufacturing issues: USFDA
Lupin is also recalling an unspecified number of penicillamine tablets in the US due to failed dissolution specifications..Sun Pharma is recalling 96,192 bottles of Liothyronine Sodium Tablets in the US due to failed impurities/degradation specifications.SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 15, 2023 for Raksha Sudhir ValiaSun Pharma's specialty product Ilumetri included in China's national reimbursement drug list
Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.